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Abstract
Autosomal recessively inherited glucocerebrosidase 1 (GBA1) mutations cause the lysosomal storage disorder Gaucher’s disease
(GD). Heterozygous GBA1mutations (GBA1+/−) are the most common risk factor for Parkinson’s disease (PD). Previous studies
typically focused on the interaction between the reduction of glucocerebrosidase (enzymatic) activity in GBA1+/− carriers and
alpha-synuclein-mediated neurotoxicity. However, it is unclear whether other mechanisms also contribute to the increased
risk of PD in GBA1+/− carriers. The zebraﬁsh genome does not contain alpha-synuclein (SNCA), thus providing a unique
opportunity to study pathogenic mechanisms unrelated to alpha-synuclein toxicity. Here we describe a mutant zebraﬁsh line
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created by TALEN genome editing carrying a 23 bp deletion in gba1 (gba1c.1276_1298del), the zebraﬁsh orthologue of human GBA1.
Marked sphingolipid accumulation was already detected at 5 days post-fertilization with accompanying microglial activation
and early, sustained up-regulation ofmiR-155, amaster regulator of inﬂammation. gba1c.1276_1298delmutant zebraﬁsh developed
a rapidly worsening phenotype from 8 weeks onwards with striking reduction in motor activity by 12 weeks.
Histopathologically,we observedmarkedGaucher cell invasionof the brain and otherorgans. Dopaminergic neuronal cell count
was normal through development but reduced by >30% at 12 weeks in the presence of ubiquitin-positive, intra-neuronal
inclusions. This gba1c.1276_1298del zebraﬁsh line is the ﬁrst viable vertebratemodel sharing key pathological features of GD in both
neuronal and non-neuronal tissue. Our study also provides evidence for early microglial activation prior to alpha-synuclein-
independent neuronal cell death in GBA1 deﬁciency and suggests upregulation of miR-155 as a common denominator across
different neurodegenerative disorders.
Introduction
Gaucher’s disease (GD) is the most common lysosomal storage
disorder with a prevalence of 1:40 000 (1). It is caused by auto-
somal recessively inherited homozygous or compound heterozy-
gousmutations in glucocerebrosidase 1 (GBA1). GBA1 is a lysosomal
enzyme required for the breakdown of glucosylceramide to cera-
mide and glucose and forms part of the sphingolipid pathway.
The pathological hallmark of GD is the accumulation of charac-
teristic macrophages engorged with glycolipids also known as
Gaucher cells. Clinically, GD can present heterogeneously with
three different subtypes, categorized by severity and distribution
of symptoms. Patients with type I can be virtually asymptomatic,
type II presents with rapid neurological decline and subsequent
death within the ﬁrst 3 years of life, whereas type III presents
with neurological decline during adolescence (2). Current treat-
ment options largely focus on enzyme replacement therapy,
which is effective for the treatment of non-neurological compli-
cations of GD but ineffective for the treatment or prevention of
neurological complications due to its inability to cross the
blood–brain barrier (3).
Heterozygous GBA1 mutations (GBA1+/−) are the most com-
mon risk factor for Parkinson’s disease (PD) with an odds ratio
of >5 (4–6). PD patients carrying such a heterozygous GBA1muta-
tion have an earlier age of onset and are more likely to develop
impaired cognitive function (7,8).
Both toxic gain of function and loss of function mechanisms
have been proposed to explain the link between heterozygous
GBA1 mutations and PD with particular focus on an interaction
between glucocerebrosidase 1 (GCase) enzymatic activity and
alpha-synuclein (6,9).
GBA1 knock out (KO) mouse die shortly after birth due to skin
defects leading to a loss of hydration. Conditional GBA1 KO mice
with isolated neuronal GCase deﬁciency have an initial, symp-
tom-free period of 10 days, followed by rapid neurological decline
and subsequent death due to excessive seizures. Conditional KO
mice in the hematopoietic andmesenchymal cell lineagesmodel
themajor visceral symptoms of GD, but otherwise have a normal
life span and fail to model the neuropathic forms (10).
Zebraﬁsh have become a versatile disease model for studying
neurodegeneration (11). As vertebrates, they are more closely re-
lated to humans thanDrosophila or Caenorhabditis elegans, develop
externally and are transparent. We and others have previously
demonstrated their usefulness to identify novel drug targets in
zebraﬁsh models of PD and other neurodegenerative disorders
(12,13).
We have used the TALEN (transcription activator-like effector
nucleases) approach to create a gba1mutant zebraﬁsh. Homozy-
gous gba1 mutant zebraﬁsh (gba1−/−) develop normally but al-
ready display sphingolipid dysregulation and accumulation as
early as 5 days post-fertilization (dpf ) with marked alterations
of the GD biomarkers β-hexosaminidase and chitotriosidase in
juvenile brain tissue.We further demonstrate earlymicroglial ac-
tivation with marked upregulation of miRNA-155 (miR-155)
which precedes subsequent organ inﬁltration with Gaucher
cells in juvenile gba1−/−. These gba1−/− zebraﬁsh also develop pro-
gressive neurodegeneration, mitochondrial dysfunction and loss
of dopaminergic neurons with ubiquitin-positive inclusions in
the absence of alpha-synuclein. This new vertebrate model of
GCase deﬁciency is likely to have utility for future gene–gene
interaction studies and in vivo drug screens. The identiﬁcation
of distinct and potentially ‘druggable’ molecular targets such as
miR-155 will facilitate these in vivo drug screens.
Results
Zebraﬁsh possess a single GBA1 orthologue
ABLAST search identiﬁed a single zebraﬁsh orthologue of human
GBA1 on chromosome 16 (ENSDARG00000076058) of the zebraﬁsh
genome. The zebraﬁsh gene (gba1) encodes a single protein of 518
amino acids and 57% identity with the human orthologue. The
genetic loci of both (human) GBA1 and (Danio rerio) gba1 shared
conserved synteny, both containing the genes RUSC1, FDPS
and DAP3 within 500 kb of each orthologue. gba1 was expressed
at constant levels through 1–5 dpf with more marked expression
in the brain. Expressionwas also detected in adult brain and liver
tissue, organs speciﬁcally affected by GD pathology (Fig. 1A–D).
gba1 TALEN-generated mutants are loss of function
Using TALEN technology, we generated a gba1mutant containing
a 23 bp deletion in exon 7 (c.1276_1298del, Fig. 1E and Supple-
mentary Material, Fig. S1). The deletion results in a frame-shift
at position c.1276 and a subsequent premature stop codon
66 bp downstream, within exon 7 at c.1342 (p.379). The
gba1c.1276_1298del (from hereon referred to as gba1−/−) resulted in
a reduction of gba1 mRNA by >50% (P < 0.01, Fig. 1F). Similarly,
GCase activity was reduced in gba1−/− brains by >50% (P < 0.05)
compared with wild-type (Fig. 1G).
Analysis of sphingolipid metabolites
GCase deﬁciency leads tomarked sphingolipid dysregulation and
accumulation of GCase substrates in Gba1 KO mice and patients
with GD (14–16). We analyzed sphingolipid metabolites by mass
spectrometry across all gba1 genotypes and identiﬁed marked
accumulation of sphingolipid metabolites as early as 5 dpf in
gba1−/−, with increases in the C18 molecular weight species
of each glycolipid being the most pronounced (Fig. 2). Hexosyl-
sphingosine was virtually undetectable in wild-type samples
but increased to 1573% in gba1−/− of the level seen in controls
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(Fig. 2C; P < 0.0001), glucosylceramide was increased to ∼360%
(Fig. 2D; P < 0.0001). Substrates upstream of GCase also accumu-
lated, namely lactosylceramide to nearly 300% (Fig. 2F; P < 0.0001)
whereas galactosylceramide was notably decreased by 50%
(Fig. 2E; P < 0.01). Mass spectrometric analysis was repeated in ju-
venile brain tissue at 12 weeks post-fertilization (wpf) across all
gba1 genotypes. Again, direct substrates of GCase had the largest
increases in gba1−/− brains: hexosylsphingosinewas virtually un-
detectable in wild-type brains but increased in gba1−/− to 2734%
of the level seen in controls (Fig. 2I; P < 0.0001), whereas glucosyl-
ceramide increased to 14 000% (Fig. 2J; P < 0.0001). Galactosylcer-
amide was now increased as well (Fig. 2K; P < 0.0001) but not as
strongly as lactosylceramides which increased above wild-type
levels to 2000% of the level seen in controls (Fig. 2L; P < 0.0001).
Sphingosine levels were unaltered in 5 dpf larval homogenates
but doubled in gba1−/− juvenile brains (Fig. 2A and G, P < 0.0001),
sphinganine levels were increased to a similar extent in gba1−/−
larvae and juvenile brains (Fig. 2B and H, P < 0.01). In contrast,
there were no signiﬁcant changes for any of the analyzed
sphingolipidmetabolites in either gba1+/− larvae or gba1+/− juven-
ile brains compared with wild-type (see also Supplementary Ma-
terial, Table S1 which lists all metabolites analyzed).
gba1−/− zebraﬁsh mirror key Gaucher’s disease
phenotypes
gba1−/− and gba1+/− did not develop an overt morphological
phenotype during early development. By 8 wpf, gba1−/− ﬁrst
began to swim more slowly and to generally look less well. By
12 wpf, juvenile gba1−/− developed a curvature of the spine, remin-
iscent of the gibbus formation seen in conditional mouse KO
models (Fig. 3A and B) (17). The oldest gba1−/− ﬁsh reached an
age of 14 wpf before death during pilot longevity studies. Conse-
quently, all gba1−/− ﬁshwere culled at 12 wpf for humane reasons.
Chitotriosidase and β-hexosaminidase activity are markedly
increased in the serum of GD patients and used as biomarkers
to monitor disease activity (1). In gba1−/− zebraﬁsh brains, chito-
triosidase activity was increased ∼10-fold in gba1−/− brains (P <
0.0001; Fig. 3C) without a change in gba1+/−. Similarly, β-hexosa-
minidase activity was increased to 350% of values observed in
controls (P < 0.0001) at 12 wpf but no difference was observed in
gba1+/− brains (P > 0.05; Fig. 3D). In contrast, β-galactosidase activ-
ity remained unchanged in its activity across all genotypes (data
not shown).
At 12 wpf, gba1−/− showed a reduction in total displacement of
50% (P < 0.001), with a reduction by 25% in gba1+/− (P > 0.05)
(Fig. 4A). When individual swimming movements were assigned
to low, medium and high speeds, wild-type ﬁsh spent the major-
ity of their time making fast movements (Fig. 4B and C). The op-
posite was true of gba1−/− ﬁsh, which spent most of their time
making slow movements or remaining stationary (P < 0.0001,
Fig. 4B and E). gba1+/− ﬁsh had an intermediate phenotype for
all speeds, but these changes were not signiﬁcantly different to
either wild-type or gba1−/− (Fig. 4B and D). In addition, there
were obvious defects of balance, with the gba1−/− animals show-
ing severe variability of vertical body axis orientation (roll) during
swimming, resulting in a ‘corkscrew’ pattern of motion. Occa-
sional episodes were observed in which gba1−/− animals showed
bursts of high-velocity movements, often violently moving in
circles. These abnormalities were frequently interrupted by
longer periods of inactivity during which the gba1−/− zebraﬁsh
lay on the tank ﬂoor (Supplementary Material, Video). These
Figure 1. gba1 expression inwild-type (WT) zebraﬁsh and loss of function studies. gba1 expression through early development and in adult organs particularly affected by
GD (namely brain and liver) was conﬁrmed by RT–PCR (A); ef1awas used as a loading control. WISH conﬁrmed early expression of gba1 in brain tissue at 1 dpf (B), 2 dpf (C)
and 3 dpf (D). Using TALENs, a 23 bp deletion in exon 7 of gba1 (gba1c.1276_129del) was generatedwhich could be genotyped by PCR. A representative genotyping gel (E) shows
WT (lane 1), gba1+/− (lane 2) and gba1−/− (lane 3). The gba1c.1276_129delmutation resulted in a >50% decrease in gba1 transcript levels in gba1−/− brain tissue (P < 0.01, F) and a
decrease in enzymatic GCase activity (P < 0.05, G). *P < 0.05; **P < 0.01.
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abnormalities were not seen in any of the heterozygous or wild-
type sibling controls.
gba1−/− exhibit Gaucher cell organ invasion and
microglial activation
The primary histopathological hallmark of GD is the formation
and accumulation of lipid-engorgedmacrophages knownasGau-
cher cells leading to visceral organomegaly. Microglial activation
and other immunemechanisms have also been implicated in the
pathogenesis of neuronal cell death in both GD and PD (18–20).
Hematoxylin and eosin (H&E) staining in 12 wpf gba1−/− revealed
marked inﬁltration with enlarged ‘Gaucher-like’ cells not only in
the brain (Fig. 5B), but also in liver (Fig. 5C), thymus (Fig. 5D) and
pancreas (datanot shown). As expected, no overt pathology could
be detected in wild-type control individuals (Fig. 5A). Gaucher
cellswere periodic acid Schiff (PAS)-positive, indicative of glycolipid
accumulation (data not shown). No abnormalities could be de-
tected in thewild-type or gba1+/−ﬁsh. Therewasnoovert pathology
at all in any of the three genotypes at 4 wpf (data not shown).
These Gaucher-like cells around the tectal ventricle labeled
strongly with the 4.C4 monoclonal antibody marker for zebraﬁsh
monocyte/macrophage lineage cells (Fig. 5E and F). In addition,
there was a marked increase in microglial cells in the brain
parenchyma of gba1−/− zebraﬁsh compared with controls
(Fig. 5G and I). The microglia in gba1−/− brains showed swollen
cell bodies and retracted processes typical of microglial activa-
tion (Fig. 5H and J).
The transparent nature of zebraﬁsh embryos allows the assess-
ment of microglial activation in vivo in a zebraﬁsh transgenic line
inwhich themembrane-targetedﬂuorescent reporter (GFP-CAAX)
expression is driven by the promoter of macrophage-expressed
Figure 2. Sphingolipid metabolites accumulate in zebraﬁsh larvae and brain tissue. Sphingolipid metabolites were analyzed across gba1 genotypes in 5 dpf larvae and
12 wpf brain tissue. Sphingosine levels remained unaltered across all genotypes at 5 dpf (A) but were approximately doubled in gba1−/− brains at 12 wpf (G). In
contrast, sphinganine (B), hexosylsphingosine (C), glucosylceramide C18.0 (D) and lactosylceramide C18.0 (F) had already accumulated in gba1−/− larvae up to 1500% of
control values, whereas galactosylceramide C18.0 (E) levels were reduced by 50%. In 12 wpf brain tissue, all these sphingolipidmetabolites had accumulated in gba1−/− by
up to 14 000% (G–L). The concentration of each sphingolipid is given in ng/mg (ns: non-signiﬁcant; **P < 0.01; ****P < 0.0001).
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gene 1 (mpeg1). We crossed this mpeg1:GFP-CAAX transgenic line
with gba1+/− zebraﬁsh and then assessed microglial activation in
larvae at 4 dpf across the three different genotypes to further deter-
mine whether altered immune mechanisms may precede overt
neuropathology. gba1+/− and gba1−/− had altered microglial shape,
reﬂecting microglial activation (shape factor in wild-type controls:
0.2077; gba1+/−: 0.2319; gba1−/−: 0.2356; P < 0.001 for both gba1+/−
and gba1−/−; Fig. 6A). Microglia vacuole count was also increased
in gba1−/− microglia by 40% with average count across genotypes
being 3.737 (wild-type), 4.015 (gba1+/−, P > 0.05) and 5.273 (gba1−/−, P
< 0.0001) per microglia (Fig. 6B). In contrast, microglia volume and
absolute count were unchanged across the three genotypes (data
not shown).miR-155 is a key regulator of inﬂammation (21).Wehy-
pothesized that miR-155 up-regulation may be an early feature in
gba1−/−. As predicted, miR-155 levels were increase by 88% in
gba1−/− larvae at 5 dpf compared with values observed in controls
(P< 0.05, Fig. 6C), with an evenmoremarked increase by 470% in ju-
venile gba1−/− brain tissue (P < 0.01, Fig. 6D).
gba1−/− undergo alpha-synuclein-independent
neurodegeneration
The alpha-synuclein (SNCA) gene is notably absent in the zebraﬁsh
genome, but zebraﬁsh possess orthologues of beta- and gamma-
synuclein (22). To further investigate the effect of partial or com-
plete GCase deﬁciency in the absence of alpha-synuclein (pro-
tein), dopaminergic neuronal cells were counted both during
Figure 3. Skeletal and biochemical indices ofGCasedeﬁciency. At 12 wpf gba1−/− (A)
developed a curve to their spine compared with wild-type (WT) controls (B) in a
similar manner to some conditional GBA1 KO mice (17). The difference in the
stripe pattern of gba1−/− (A) and wild-type zebraﬁsh (B) is due to the gba1+/− line
being of mixed lineage with (wild-type) AB and (wild-type) TL genetic
background. Classical Gaucher disease biomarkers were markedly elevated in
gba1−/− brains at 12 wpf, with a 10-fold increase in chitotriosidase activity
(P < 0.0001) (C) and a 4-fold increase in β-hexosaminidase activity (P < 0.0001) (D).
No signiﬁcant changeswere detected in either assay in gba1+/− brains. ****P <0.0001.
Figure 4.Marked slowing of spontaneousmotor activity in gba1−/−. Video-tracking
software was utilized to measure locomotion in gba1 genotypes. All ﬁsh were
ﬁlmed from the side. gba1−/− exhibited a 50% decrease in total displacement (A)
(P < 0.001). When speeds were segregated into small medium and high speeds
(B), gba1−/− spent more time moving at low speeds (300%, P < 0.0001) and a spent
less time moving at high speeds (88% less, P < 0.0001). For representative
movements traces of wild-type (WT) (C), gba1+/− (D) and gba1−/− (E), red lines
represent high-speed movements, green represents medium-speed movements
and black represents low-speedmovements. ns, P >0.05; ***P < 0.001; ****P < 0.0001.
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development and in juvenile zebraﬁsh. At 5 dpf, therewas no dif-
ference between either gba1+/− or gba1−/− and wild-type controls
in the number of ascending dopaminergic neurons within the
posterior tuberculum, the anatomical structure in zebraﬁsh
analogous to the human substantia nigra pars compacta (Fig. 7A).
By 12 wpf, however, there was a marked reduction
of dopaminergic neurons in both the caudal hypothalamus
by 40% (P < 0.01; Fig. 7B) and the posterior tuberculum by ∼30%
(P < 0.01; Fig. 7C). These data show unequivocally that dopamin-
ergic neurons degenerate in gba1−/− zebraﬁsh. Unexpectedly,
both beta- and gamma-synuclein protein levels were markedly
reduced by 60% in gba1−/− brains (P < 0.0001; Fig. 7D and E).
Microscopically, there was an abundance of ubiquitylated neur-
onal cytoplasmic inclusions as well as occasional ubiquitylated
neurites throughout the CNS, but most prominently in the larger
hindbrain neurons of gba1−/− ﬁsh at 12 wpf (Fig. 7H and I) which
bear resemblance to Lewy bodies and Lewy neurites in post-
mortem PD brain tissue (Fig. 7J).
gba1−/−-inducedmitochondrial dysfunction and impaired
autophagy
Mitochondrial dysfunction has been demonstrated in othermod-
els of gba1 deﬁciency (23). We analyzed the activity of the
Figure 5. gba1 deﬁciency leads to Gaucher cell invasion and increased abundance of activated microglia in gba1−/− brain. H&E staining of 12 wpf sections demonstrated
Gaucher cell (black arrows) organ invasion of the tectal ventriclewithin the brain of gba1−/− (B), comparedwithwild-type (WT) brains (A). Gaucher cell organ invasion was
also present in the visceral organs of gba1−/− such as the liver (C) and thymus (D). Fluorescent images show confocalmicrographs of gba1−/− andwild-type siblings control
brains labeled by indirect immunoﬂuorescence for 4.C4 (macrophages andmicroglia; green), DAPI (nuclei; blue) and P0 (myelin; red). Low-power images through the tectal
ventricle showed accumulation of 4.C4 immunoreactivemacrophages in the ventricle and periventricular region of gba1−/− (F) but not wild-type brain (E). Microgliawithin
the brain parenchyma were identiﬁed by their immunoreactivity to 4.C4 and typical morphology (G and I). Compared with wild-type brain (G), microglial were more
numerous and brightly labeled in gba1−/− brain (I). In addition, compared with the typical quiescent morphology of microglia seen in wild-type brain (H), marked
rounding of the cell body and retraction of processes was apparent in gba1−/− brain (J). The white arrows point at a normal microglial cell body in a wild-type control
brain (H) and a rounded microglial cell body in a gba1−/− brain (J); the white arrow heads point at a normal, extended microglial process in a wild-type control brain (H)
and at a retracted microglial process in a gba1−/− brain (J). These morphological changes are typical of microglial activation.
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mitochondrial respiratory chain in 12 wpf brain tissue across the
gba1 genotypes. Complex III and IV activity was lower by ∼50% in
gba1−/− compared with wild-type (P < 0.05). Both complex III and
IV activity in gba1+/− ﬁsh had intermediate values between those
seen in gba1−/− andwild-type, but did not differ signiﬁcantly from
either (Fig. 8A and B).We hypothesized that the observed speciﬁc
abnormalities inmitochondrial function seen in gba1−/− ﬁshmay
be due to impaired mitochondrial biogenesis or mitochondrial
protein turnover, possibly linked to impaired mitophagy. How-
ever, the outer mitochondrial membrane protein TOMM20 and
TIMM9 (located in the inter membrane space) levels were similar
across the three genotypes (datanot shown). In contrast, NDUFA9
(encoding a complex I subunit) and Cox4i1 (encoding a complex
IV subunit) were reduced in gba1−/− brains compared with con-
trols (Fig. 8C and D, P < 0.01). The reduction of Cox4i1 may at
least in part underlie the observed lowering of complex IV activ-
ity. ATP5A (encoding a complex V subunit) was also somewhat
lower in gba1−/− ﬁsh but this difference was not signiﬁcant (P >
0.05; data not shown).
GCase deﬁciency results in lysosomal dysfunction due to the
accumulation of its substrate, glucocerebroside and inmice lack-
ing Gba1, decreased autophagosome formation and accumula-
tion of autophagy substrates in the brain as well as decreased
mitophagy has been observed (23). Therefore, we investigated
whether autophagy was disrupted in the brains of 12 wpf gba1
mutants compared with wild-type siblings. LC3-II is speciﬁcally
targeted to autophagosomal membranes and strongly correlates
with the number of autophagosomes (24). Brains from gba1−/−
ﬁsh had more than 2-fold increase in LC3-II levels compared
with wild-type siblings (Fig. 8E and F; P < 0.01). Whereas this dif-
ference in LC3-II levels clearly demonstrates that autophago-
some number is altered in gba1−/− brains compared with those
of wild-types, it is unclear whether autophagosome formation
is increased orwhether autophagosome degradation is defective,
because both of these scenarios would lead to an increase in LC3-
II levels.
Discussion
Modern gene editing techniques such as the TALEN strategy have
transformed zebraﬁsh research (25).We have used the TALEN ap-
proach to generate a gba1mutant zebraﬁsh line which faithfully
resembles key pathological and biochemical features of human
GCase deﬁciency. We provide data on gba1−/−mRNA stability, re-
duced GCase enzymatic activity and other biochemical readouts
including extensive mass spectrometry-based analysis of sphin-
golipids which all support the presence of a marked biological
effect caused by the TALEN-induced 23 bp deletion in gba1 on
GCase function.
This zebraﬁshmodel of GCase deﬁciency is the ﬁrst vertebrate
model to faithfully replicate key GD pathology in both visceral
and neural tissue simultaneously. Conventional KO and condi-
tional KO mice model either neuropathic or non-neuropathic
Figure 6. Activation of inﬂammatory/immune mechanisms during larval stages.
Microglia in 4 dpf gba1+/− and gba1−/− had an increase in shape factor (sphericity)
(P < 0.001 for both) indicative ofmicroglial activation (A). Additionally, the number
of vacuoles in gba1−/−was increased by 40% comparedwith the values observed in
wild-type (WT) controls (P < 0.0001) (B). Levels of miR-155, a master regulator of
inﬂammatory/immune mechanisms, were analyzed in 5 dpf larvae (C) and
12 wpf brain tissue (D) across gba1 genotypes. miR-155 was increased 2-fold
in gba1−/− larvae (P < 0.05) and 4-fold in 12 wpf gba1−/− brains (P < 0.01). *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001.
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Gaucher disease but not both (10). Our extensive glycolipid mass
spectrometry analysis suggests that it is mostly lower MW spe-
cies which accumulate, with high MW species either unchanged
or decreased compared with wild-type. The predominant in-
crease of C18 metabolites is in keeping with similar studies in
other model systems (16,26,27). Our observation of a marked in-
crease in the accumulation of distinct glycosphingolipids prior
to the onset of marked inﬂammation and neuronal cell loss in
GCase deﬁcient zebraﬁsh larvae is in keeping with similar obser-
vations in a mouse model of neuronopathic GD (14). miR-155 is a
master regulator of pathways involved in the regulation of im-
mune mechanisms (21) that is expressed in both the innate and
the adaptive immune system and predominantly acts viamoder-
ate mRNA degradation. Of note, miR-155 upregulation has al-
ready been implicated in the pathogenesis of different
neurodegenerative disorders. Early miR-155 upregulation contri-
butes to neuroinﬂammation in an Alzheimer’s disease transgenic
mouse model as well as in Aβ-activated microglial and astrocyte
cultures (28). Expression levels of miR-155 are increased in the
spinal cordof both familial andsporadic amyotrophic lateral scler-
osis and genetic ablation of miR-155 markedly increased survival
in SOD1 mice with restoration of abnormal microglia (29). How-
ever, miR-155 had not been implicated in the pathogenesis of GD
or PD before now. Our study clearly suggests that activation of im-
munemechanisms precedes neuronal cell loss rather thanbeing a
consequence of it. Future work needs to determine whether miR-
155may also be a promising ‘druggable’ target for neuroprotective
therapy in both GD and PD. Of note, an association of GBA muta-
tion status with an increase in the plasma levels of different in-
ﬂammatory mediators such as interleukin 8 has been reported
in PD patients (30).
Both loss of GCase function and toxic gain of function have
been proposed to explain the increased risk of PD for GBA1+/− car-
riers (6,31). There is also strong evidence for an interplay between
GCase activity and alpha-synuclein levels (9,16,32). The marked
loss of dopaminergic neurons in gba1−/− zebraﬁsh in the absence
of alpha-synuclein indicates that alpha-synuclein-independent
mechanisms can contribute to the neurodegeneration resulting
from GCase deﬁciency. The extensive accumulation of ubiqui-
tin-positive intra-neuronal inclusions in the brains of juvenile
gba1−/− zebraﬁsh further suggests that proteins other than
alpha-synuclein accumulate in this model. Obvious candidates
are the β- and γ1-synucleins expressed in the zebraﬁsh CNS
(22). However, western blot analysis showed that these are both
markedly reduced in juvenile gba1−/− brains, possibly as a conse-
quence of extensive synaptic loss accompanying neurodegenera-
tion in this model. Indeed, neuronal ubiquitinopathy preceding
an increase in alpha-synuclein levels has been described in a
GBA1 knock-in mouse model (33) and it is likely that gba1−/−
zebraﬁsh represent an example of non-synuclein proteinopathy
and synuclein-independent neurodegeneration occurring in the
absence of GCase activity.
Mitochondrial dysfunction with impaired quality control has
been reported in a mouse model of GD and iPSC-derived GBA1+/−
neurons (16,23). However, we observed reduced complex III and
IV activity rather than reduced complex I activity as observed in
GBA1−/− mice (23). We hypothesize that this may at least in part
be due to alpha-synuclein-mediated mitochondrial toxicity in
GBA1−/− mice which typically affects complex I activity (34). The
reduced complex IV activity in gba1−/− juvenile zebraﬁsh brains
may be due to a direct effect of the markedly elevated glucosyl-
sphingosine, a potent inhibitor of the mitochondrial cytochrome
c oxidase on the environment of this membrane-bound enzyme
(35). Interestingly, magnetic resonance spectroscopic imaging
data in human patients also provide circumstantial evidence of
alteredmembrane phospholipid metabolism in GBA1-associated
PD (36). Alternatively, the reduced complex IV activity may at
least partially be due to the observed reduction in the Cox4i1 pro-
tein level the gba1−/− brains (Fig. 8D). Autophagy plays an essen-
tial role in the clearance of aggregate-prone proteins and
damaged mitochondria, and dysfunctional autophagy has been
implicated in the pathogenesis of PD (37). In mouse models of
GCase deﬁciency, autophagosome formation is decreased and
ubiquitylated proteins monomeric and oligomeric forms of
Figure 7.Dopaminergic neuronal cell loss and ubiquitinated inclusions in gba1−/− brains. The number of ascending diencephalic dopaminergic neurons (Rink–Wullimann
groups 1, 2, 4 and 5) was similar across the three gba1 genotypes at 5 dpf (A). In contrast, there was a 40% loss (P < 0.01) of the dopaminergic neurons in the caudal
hypothalamus (B) and a 30% loss (P < 0.01) in the posterior tuberculum at 12 wpf (C). β (D) and γ1 (E) synuclein proteins levels were reduced by 60% in gba1−/− brain
tissue suggesting a distinct loss of synapses due to global neurodegeneration. F–J: IHC labels ubiquitin brown by 3,3′-DAB. Glial cell nuclei are highlighted by
hematoxylin counterstaining (blue). At 12 weeks of age, there is no signiﬁcant pathology in wild-type (WT) (F) or gba1+/− ﬁsh (G). In contrast, gba1−/− ﬁsh (H and I) have
granular ubiquitylated neuronal cytoplasmic inclusions (black arrows) and ubiquitylated neuritic pathology (white arrow). These granular neuronal cytoplasmic
inclusions and neurites resemble the granular aggregates of a-synuclein (black arrow) and Lewy neurites (white arrow) as seen in sporadic PD (J; substantia nigra)
(scale bar = 50 μm throughout). ns, P > 0.05; **P < 0.01; ****P < 0.0001.
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alpha-synuclein and ubiquitylated proteins accumulate in the
brain (23). In juvenile gba1−/− zebraﬁsh brains, we observed a sig-
niﬁcant increase in LC3-II levels which may result from either an
increase in autophagosome formation or a defect in degradation.
Someof ourﬁndingsare remarkablysimilar toobservations ina
GBA1 nonsense medaka (Oryzias latipes) model of Gaucher disease
(27). Future studies need to reveal whether the observed early
microglial activation and subsequent neuronal cell loss is linked
to the recently reportedWnt signaling abnormalities inGCase1 de-
ﬁcientD. reriozebraﬁshwith reducedCGaseactivity causedby tran-
sient antisense knockdown of gba1 early in development (38).
Conclusion
Zebraﬁsh are an excellent vertebratemodel to study human brain
diseases and increasingly used for high-throughput drug screens
(39,40). The large sphingolipid accumulation and microglial dys-
function during larval stages shows the potential to use the gba1
mutant zebraﬁsh as a tool for phenotypic drugdiscovery to identify
new disease modifying therapies for neuronopathic GD and to aid
in the identiﬁcation of novel PD toxins that may act synergistically
in conjunction with gba1+/−. There is growing evidence of lyso-
somal impairment in PD in general and decreased activity of
GCase in particular, even in the absence of GBA1 mutations
(32,41–44). Augmenting CNS GCase activity has been proposed as
a promising therapeutic strategy for PDand otherGD-related synu-
cleinopathies (45). A further promising aim for zebraﬁsh in vivo
high-throughput screens could therefore be to identify compounds
which would upregulate neuronal GCase activity.
Materials and Methods
Zebraﬁsh husbandry
All larval and adult zebraﬁsh were housed at the University of
Shefﬁeld; experimental procedures being in accordance with
Figure 8.Mitochondrial dysfunction and autophagy in gba1−/− zebraﬁsh. Therewas a 50% decrease (P < 0.05) in complex III (A) and complex IV (B) activity in gba1−/− brains
at 12 wpf. Therewas also a decrease in the protein levels of the complex I subunit NDUFA9 (C, P < 0.01) and the complex IV subunit Cox4i1 (D, P < 0.01). LC3-II was increased
2-fold in gba1−/− brains at 12 wpf compared with wild-type (WT) (E, P < 0.01). (F) A representative western blot of LC3-II protein levels in wild-type and gba1−/− zebraﬁsh
brains. *P < 0.05; **P < 0.01.
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UK Home Ofﬁce Animals (Scientiﬁc Procedures) Act 1986 (Project
license PPL 70/8437, held byDrOliver Bandmann). Adult zebraﬁsh
were housed at a density of 40 per tank,whereas on a cycle of 14 h
of light, 10 h of dark. Adults and embryos were kept at constant
temperature of 28°C.
gba1 stable mutant line
A stable loss of function allele was generated with the TALEN
genome editing system targeting an mwoI restriction enzyme
site located within exon seven of gba1. A pair of TALENs binding
5′TCTGTACCCTGATTACTT (right TALEN) and 5′ATGCGCTGG
GTGGAGTCCA (left TALEN) were chosen by the TALEN targeter
(https://boglab.plp.iastate.edu/node/add/talen). TALEN mRNA
was generated and injected into one cell stage Zebraﬁsh embryos.
F0 mosaic founders were identiﬁed and outcrossed to wild-type
TL adults. A (heterozygous) allele was identiﬁed in the F1 gener-
ation containing a 23 bp deletion (gba1+/−) and outcrossed again
to TL until the F3 generationwas reached. Zebraﬁsh homozygous
for this 23 bp deletion (gba1−/−) used for all experiments were
generated from an incross of F3 gba1+/−. All zebraﬁsh were geno-
typed using primers F-5′AAAGCAGCACGATATGTCCA and R-5′
ATGTCATGGGCGTAGTCCTC. DNA was ampliﬁed and analyzed
on a 2% agarose gel.
Gene expression analysis
RNA was extracted from 20 zebraﬁsh embryos/zebraﬁsh caudal
hypothalamus by 40% (P < 0.01; Fig. 7B) and the posterior tubercu-
lum by ∼30% (P < 0.01; Fig. 7C). brains (two per replicate) at spe-
ciﬁc time points using TRIzol® (Life Technologies™). A Verso
cDNA synthesis kit (Thermo Scientiﬁc) was used to generate
cDNA. Quantitative real-time PCR (qPCR)-based quantiﬁcation
of gba1 expression was undertaken using primers F-5′GGCA-
CAGGCTCTATCTGCTC and R-5′TCTAGAAACCTGATATAGT.
SYBR (Life Technologies™) green was used for all qPCR experi-
ments, with ef1a as a reference gene (ef1a primers: F-5′
TGGTACTTCTCAGGCTGACT and R-5′TGACTCCAACGATCAGCT
GT). For microRNA expression analysis, RNA was harvested
from embryos and brain tissue as previously described. RNA con-
centrationwas accurately quantiﬁed using the QuantiFluor™ RNA
system (Promega) and the Qubit® ﬂuorometer (Life Technologies).
100 ng of total RNA was reverse-transcribed and subsequently
qPCR was performed using Taqman miRNA assays (Applied Bio-
systems). A Taqman probe (sequence: 5′UUAAUGCUAAUCGU-
GAUAGGGG) was used to quantify miR-155 levels.
Lysosomal enzyme analysis, assessment
of mitochondrial respiratory chain function
and mass spectrometry
All lysosomal enzyme assays were performed on homogenates
of whole zebraﬁsh brain at 12 wpf with a protein concentration
of 1 mg/ml and at 28°C unless otherwise stated. All assays were
stopped with 1 M glycine NaOH buffer pH 10.4 and used 1 n
4-methylumbelliferone (Sigma) as a standard to calculate
the ﬁnal result. Chitotriosidase activity was measured using
4-methylumbelliferyl-β--N,N′,N″-triacetyl-chitotriose (Sigma)
in McIlvaine citrate–phosphate buffer pH 5.2. β-Hexosaminidase
activity wasmeasured using 4-methylumbelliferyl-2-acetamido-
2-deoxy-β--gluco-pyranoside (Sigma) inMcIlvaine citrate–phos-
phate buffer pH 4.5. Beta-galactosidase activity was measured
using 1 m 4-methylumbelliferyl--galactopyranoside dissolved
in McIlvaine citrate–phosphate buffer pH 4.1. GCase activity was
measured with 5 m 4-methylumbelliferyl-β--glucopyranso-
side (Sigma) in McIlvaine citrate–phosphate buffer pH 5.4 in the
presence and absence of conduritol B epoxide at 37°C.
Mitochondrial complex activities I–IV were assessed in whole
brain homogenates at 12 wpf as previously described (46).
Mass spectrometry for the detection of sphingolipid metabo-
lites was undertaken at 5 dpf and 12 wpf as previously described
(47). Larvae were genotyped as previously described (48). Geno-
type larvae were then frozen in liquid nitrogen in groups of 20
per genotype (wild-type, gba1+/− and gba1−/−) and stored at −80°
C prior to mass spectrometric analysis. Mass spectrometry was
then also undertaken in brains of juvenile zebraﬁsh (12 wild-
type, 10 gba1+/− and 10 gba1−/−) at 12 wpf.
Assessment of dopaminergic nervous system
Dopaminergic neurons were ﬁrst counted at 5 dpf using whole
mount in situ hybridization (WISH) staining with a probe for tyro-
sine hydroxylase (TH) (n = 10 embryos per genotype and biological
replicate). Dopaminergic neurons were counted by eye using an
axioplan compound microscope (Zeiss) at 20× magniﬁcation as
previously described (46). The counter was blinded to the geno-
type and condition. The dopaminergic neuron count was as-
sessed by counting the distinct neuronal subgroups one, two,
four and ﬁve in the diencephalon, deﬁned according to the Rink
and Wullimann classiﬁcation (49,50). The mean neuron count of
each control group was normalized to 100% and all other group
counts expressed as a percentage of the control group. Juvenile
zebraﬁsh were culled and brains ﬁxed in paraformaldehyde
(PFA) to enable dopaminergic neuronal cell count at 12 wpf in
wild-type, gba1+/− and gba1−/− zebraﬁsh. Dopaminergic neurons
were stained using a TH1 antibody (Mouse monoclonal anti-TH,
DiaSorin Inc.) and then counted in the posterior tuberculum and
caudal hypothalamus as previously described (51).
Movement analysis
Locomotion was quantiﬁed using Viewpoint analysis software
version 3, 22, 3, 9 (Viewpoint). Fish were ﬁlmed individually
from the side, for 10 min following 10 min acclimation time.
Low-speed movements were deﬁned as <5 cm/s. Medium-speed
movements were deﬁned as 5< X <7 cm/s. High-speed move-
ments were deﬁned as movements >7 cm/s.
Microglial activation
gba1+/−were crossed to Tg(mpeg1:GFP-CAAX) (mpeg1,sh425), simi-
lar to a previously published protocol (52). Details on the trans-
genesis methods are available from the authors. All subsequent
embryoworkwas generated from an incross of gba1+/− andmpeg1
and imaged at 4 dpf. High-resolution imaging was performed
using an inverted UltraViewVoX spinning-disk confocal micro-
scope (PerkinElmer Life and Analytical Sciences). Imaging was
performed to a depth of ∼150 µm from the dorsal surface of the
brain using 2 µm z-sections. Volumetric and shape factor ana-
lyses were performed using Volocity 6.3 (PerkinElmer Life and
Analytical Sciences) software, using intensity of ﬂuorescence to
identify individual cells. Measurements of vacuole diameter
were performedmanually using the line tool. Data for the assess-
ment of microglial shape and vacuole count were pooled
form three independent experiments including a total of 177
wild-type, 94 gba1+/− and 82 gba1−/− microglial cells from 15
wild-type, 9 gba1+/− and 7 gba1−/− larvae. All measurements
were performed blind to the gba1 genotype. Following
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microscopy and image analysis, embryos were genotyped for the
gba1mutation (as described earlier).
Histology
For H&E and PAS staining, zebraﬁsh were ﬁxed in Bouins ﬁxative
for 2 weeks and embedded in parafﬁn. Ubiquitylation was as-
sessed in zebraﬁsh ﬁxed in 10% buffered formalin solution for
1–2weekswith subsequent decalciﬁcation for 7 days in ethylene-
diaminetetraacetic acid. Coronal or sagittal sections were made
of ∼4 μm thickness. Each zebraﬁsh was sectioned completely
and every 10th and 11th slidewas used for subsequently staining
with either H&E or PAS. Ubiquitin immunohistochemistry (IHC)
was performed with antigen retrieval by pressure cooker at pH
6, using a polyclonal anti-ubiquitin antibody (Dako Z 0458) at a
1:1000 dilution, standard ABC methods and diaminobenzidine
(DAB) as chromogen. Prepared microscope slides were viewed
by a board-certiﬁed pathologist (A.M.), using conventional
bright-ﬁeld microscopy.
Sample preparation for IHC and confocalmicroscopy to inves-
tigate microglial activation in juvenile zebraﬁsh brains was car-
ried out as reported previously (53). Zebraﬁsh were perfused
and brains post-ﬁxed in 4% PFA, followed by cryoprotection
in PBS-sucrose. Fourteen micrometer thick cryosections were
mounted on glass slides, treated with PBS-T (0.3% Triton-X) for 1
h, blockedwith 10% goat serum in PBS for 2 h and then incubated
overnight at 4°C with primary antibodies diluted 1:20 (7.4.C4,
puriﬁed from hybridoma clone; #92092321, HPA Culture Collec-
tions, UK), 1:500 (P0) in PBS with 1% goat serum (54). Primary
antibodies were detected using Alexa-488 (anti-mouse), and
Alexa-555 (anti-rabbit) conjugated secondary antibodies (Life
Technologies, Grand Island, NY) diluted 1:1000 in carrier buffer
and sections counter labeled with 4′, 6-diamidino-2-phenylin-
dole (DAPI). Images were acquired using an Olympus Fluoview
confocal microscope and multi-ﬁeld collages made with Adobe
Photoshop.
Western blotting
Mitochondrial primary antibodies: TOMM20 (Santa Cruz), TIMM9
(Abcam), NDUFA9 (Abcam), COX4i1 (Abcam), ATP5A (Abcam),
β-ACTIN (Sigma-Aldrich). Horseradish peroxidase (HRP)-linked
secondary antibodies were used (Sigma-Aldrich). LC3 primary
antibodies: Rabbit anti-LC3 (Novus Biologicals; NB100–2220)
used at 1:1000 dilution; mouse anti-actin (Sigma A5316) used at
1:500 dilution. Secondary antibodies: Polyclonal goat anti-rabbit
immunoglobulins/HRP (Dako P0448) used at 1:5000; polyclonal
goat anti-mouse immunoglobulins/HRP (P0447) used at 1:5000.
Beta- and Gamma-synuclein primary antibodies: mAb α/β-Synu-
clein (Syn205, Cell Signaling; 1:1000) or pAb γ1-Synuclein (1:1000).
γ1-Synuclein polyclonal antibody was raised to the peptide
DFSHGGMEGGEGGEGY by immunization of rabbits (New England
Peptide) and afﬁnity puriﬁed as previously described (54). IRDye-
800 and IRDye-680 (LI-COR, Lincoln, NE) conjugated secondary
antibodies (1:10 000) enabled the blot to be imaged using anOdys-
sey Infrared Imager (catalog no. 9120; LI-COR) with a wide linear
range.
Statistical tests and analysis
Graphpad prism V.5 software (Graphpad) was used for statistical
analysis and all errors bars shown denote the mean ± SE of the
mean. All experiments were performed in biological triplicate
unless otherwise. All data were analyzed with either T test,
one-way ANOVA or two-way ANOVA.
Supplementary Material
Supplementary Material is available at HMG online.
Acknowledgements
We thank the aquarium staff at the Bateson Centre and the histo-
pathology technicians at the Shefﬁeld Institute for Translational
Neuroscience (SITraN), both University of Shefﬁeld, UK as well
as Michal Bazala (International Institute of Molecular and Cell
Biology, Warsaw, Poland) for expert assistance. The photomicro-
graph in Figure 7J is from a microscope slide supplied by the
Parkinson’s UK Brain Bank, funded by Parkinson’s UK, a charity
registered in England and Wales (258197) and in Scotland
(SC037554).
Conﬂict of Interest statement. None declared.
Funding
This work was supported by BBSRC/Lilly (PhD CASE studentship
for M.K.); Parkinson’s UK (G-1404 for O.B.); The Academy of
Finland and Sigrid Juselius Foundation (for P.P.); FishMed/EU Sev-
enth Framework Programme (no. 316125 for A.S.); Wellcome
Trust/MRC Joint call in Neurodegeneration award to the UK Par-
kinson’s Disease Consortium (WT089698 for M.G. and A.H.V.S.);
National Institute for Environmental Health Sciences (ES022644
for E.A.B.); Australian NHMRC C.J. Martin fellowship to F.E.
(GNT1054664), MRC Programme Grant (SAR; reference number
MR/M004864/1), MRC Center grant (G0700091), University of Shef-
ﬁeld Vice-Chancellor’s Fellowship (PME). Microscopy studies
were supported by a Wellcome Trust grant to the MBB/BMS
Light Microscopy Facility (GR077544AIA). Funding to pay the
Open Access publication charges for this article was provided
by Parkinson’s UK.
References
1. Grabowski, G.A. (2012) Gaucher disease and other storage dis-
orders. Hematology Am. Soc. Hematol. Educ. Program, 2012, 13–
18.
2. Baris, H.N., Cohen, I.J. andMistry, P.K. (2014) Gaucher disease:
the metabolic defect, pathophysiology, phenotypes and nat-
ural history. Pediatr. Endocrinol. Rev., 12(Suppl. 1), 72–81.
3. Zimran, A. and Elstein, D. (2014) Management of Gaucher dis-
ease: enzyme replacement therapy. Pediatr. Endocrinol. Rev., 12
(Suppl. 1), 82–87.
4. Neumann, J., Bras, J., Deas, E., O’Sullivan, S.S., Parkkinen, L.,
Lachmann, R.H., Li, A., Holton, J., Guerreiro, R., Paudel, R.
et al. (2009) Glucocerebrosidase mutations in clinical and
pathologically proven Parkinson’s disease. Brain, 132, 1783–
1794.
5. Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Anne-
si, G., Barbosa, E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A.
et al. (2009) Multicenter analysis of glucocerebrosidase muta-
tions in Parkinson’s disease.New Engl. J. Med., 361, 1651–1661.
6. Siebert, M., Sidransky, E. and Westbroek, W. (2014) Glucocer-
ebrosidase is shaking up the synucleinopathies. Brain, 137,
1304–1322.
7. Alcalay, R.N., Caccappolo, E., Mejia-Santana, H., Tang, M.,
Rosado, L., Orbe Reilly, M., Ruiz, D., Ross, B., Verbitsky, M.,
6650 | Human Molecular Genetics, 2015, Vol. 24, No. 23
Kisselev, S. et al. (2012) Cognitive performance of GBA muta-
tion carriers with early-onset PD: the CORE-PD study. Neur-
ology, 78, 1434–1440.
8. Clark, L.N., Ross, B.M., Wang, Y., Mejia-Santana, H., Harris, J.,
Louis, E.D., Cote, L.J., Andrews, H., Fahn, S., Waters, C. et al.
(2007) Mutations in the glucocerebrosidase gene are asso-
ciated with early-onset Parkinson disease. Neurology, 69,
1270–1277.
9. Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Cald-
well, G.A., Sidransky, E., Grabowski, G.A. and Krainc, D. (2011)
Gaucher disease glucocerebrosidase and alpha-synuclein
form a bidirectional pathogenic loop in synucleinopathies.
Cell, 146, 37–52.
10. Farfel-Becker, T., Vitner, E.B. and Futerman, A.H. (2011) Ani-
mal models for Gaucher disease research. Dis. Model. Mech.,
4, 746–752.
11. Bandmann, O. and Burton, E.A. (2010) Genetic zebraﬁsh
models of neurodegenerative diseases. Neurobiol. Dis., 40,
58–65.
12. Flinn, L.J., Keatinge, M., Bretaud, S., Mortiboys, H., Matsui, H.,
De Felice, E., Woodroof, H.I., Brown, L., McTighe, A., Soellner,
R. et al. (2013) TigarB causes mitochondrial dysfunction and
neuronal loss in PINK1 deﬁciency. Ann. Neurol., 74, 837–847.
13. McGown, A., McDearmid, J.R., Panagiotaki, N., Tong, H., Al
Mashhadi, S., Redhead, N., Lyon, A.N., Beattie, C.E., Shaw, P.
J. and Ramesh, T.M. (2013) Early interneuron dysfunction in
ALS: insights from a mutant sod1 zebraﬁsh model. Ann. Neu-
rol., 73, 246–258.
14. Farfel-Becker, T., Vitner, E.B., Kelly, S.L., Bame, J.R., Duan, J.,
Shinder, V., Merrill, A.H. Jr, Dobrenis, K. and Futerman, A.H.
(2014) Neuronal accumulation of glucosylceramide in a
mouse model of neuronopathic Gaucher disease leads to
neurodegeneration. Hum. Mol. Genet., 23, 843–854.
15. Kaye, E.M., Ullman, M.D., Wilson, E.R. and Barranger, J.A.
(1986) Type 2 and type 3 Gaucher disease: a morphological
and biochemical study. Ann. Neurol., 20, 223–230.
16. Schondorf, D.C., Aureli, M., McAllister, F.E., Hindley, C.J.,
Mayer, F., Schmid, B., Sardi, S.P., Valsecchi, M., Hoffmann,
S., Schwarz, L.K. et al. (2014) iPSC-derived neurons from
GBA1-associated Parkinson’s disease patients show autop-
hagic defects and impaired calcium homeostasis. Nat. Com-
mun., 5, 4028.
17. Mistry, P.K., Liu, J., Yang, M., Nottoli, T., McGrath, J., Jain, D.,
Zhang, K., Keutzer, J., Chuang, W.L., Mehal, W.Z. et al. (2010)
Glucocerebrosidase gene-deﬁcient mouse recapitulates Gau-
cher disease displaying cellular andmolecular dysregulation
beyond the macrophage. Proc. Natl Acad. Sci. U.S.A., 107,
19473–19478.
18. Hirsch, E.C., Vyas, S. and Hunot, S. (2012) Neuroinﬂammation
in Parkinson’s disease. Parkinsonism Relat. Disord., 18(Suppl.
1), S210–4212.
19. Holmans, P., Moskvina, V., Jones, L., Sharma, M., Vedernikov,
A., Buchel, F., Saad,M., Bras, J.M., Bettella, F., Nicolaou, N. et al.
(2013) A pathway-based analysis provides additional support
for an immune-related genetic susceptibility to Parkinson’s
disease. Hum. Mol. Genet., 22, 1039–1049.
20. Vitner, E.B., Farfel-Becker, T., Eilam, R., Biton, I. and Futer-
man, A.H. (2012) Contribution of brain inﬂammation to neur-
onal cell death in neuronopathic forms of Gaucher’s disease.
Brain, 135, 1724–1735.
21. Vigorito, E., Kohlhaas, S., Lu, D. and Leyland, R. (2013) miR-
155: an ancient regulator of the immune system. Immunol.
Rev., 253, 146–157.
22. Milanese, C., Sager, J.J., Bai, Q., Farrell, T.C., Cannon, J.R.,
Greenamyre, J.T. and Burton, E.A. (2012) Hypokinesia and re-
duced dopamine levels in zebraﬁsh lacking beta- and
gamma1-synucleins. J. Biol. Chem., 287, 2971–2983.
23. Osellame, L.D., Rahim, A.A., Hargreaves, I.P., Gegg, M.E., Rich-
ard-Londt, A., Brandner, S., Waddington, S.N., Schapira, A.H.
andDuchen,M.R. (2013)Mitochondria and quality control de-
fects in a mouse model of Gaucher disease–links to Parkin-
son’s disease. Cell Metab., 17, 941–953.
24. Klionsky, D.J., Abeliovich, H., Agostinis, P., Agrawal, D.K.,
Aliev, G., Askew, D.S., Baba, M., Baehrecke, E.H., Bahr, B.A.,
Ballabio, A. et al. (2008) Guidelines for the use and interpret-
ation of assays for monitoring autophagy in higher eukar-
yotes. Autophagy, 4, 151–175.
25. Auer, T.O. and Del Bene, F. (2014) CRISPR/Cas9 and TALEN-
mediated knock-in approaches in zebraﬁsh. Methods, 69,
142–150.
26. Enquist, I.B., Lo Bianco, C., Ooka, A., Nilsson, E., Mansson, J.E.,
Ehinger, M., Richter, J., Brady, R.O., Kirik, D. and Karlsson, S.
(2007) Murine models of acute neuronopathic Gaucher dis-
ease. Proc. Natl Acad. Sci. U.S.A., 104, 17483–17488.
27. Uemura, N., Koike, M., Ansai, S., Kinoshita, M., Ishikawa-
Fujiwara, T., Matsui, H., Naruse, K., Sakamoto, N., Uchiyama,
Y., Todo, T. et al. (2015) Viable neuronopathic Gaucher Disease
Model in Medaka (Oryzias latipes) displays axonal accumula-
tion of alpha-synuclein. PLoS Genet., 11, e1005065.
28. Guedes, J.R., Custodia, C.M., Silva, R.J., de Almeida, L.P., Pedro-
so de Lima, M.C. and Cardoso, A.L. (2014) Early miR-155 upre-
gulation contributes to neuroinﬂammation in Alzheimer’s
disease triple transgenic mouse model. Hum. Mol. Genet., 23,
6286–6301.
29. Butovsky, O., Jedrychowski, M.P., Cialic, R., Krasemann, S.,
Murugaiyan, G., Fanek, Z., Greco, D.J., Wu, P.M., Doykan, C.
E., Kiner, O. et al. (2015) Targeting miR-155 restores abnormal
microglia and attenuates disease in SOD1 mice. Ann. Neurol.,
77, 75–99.
30. Chahine, L.M., Qiang, J., Ashbridge, E., Minger, J., Yearout, D.,
Horn, S., Colcher, A., Hurtig, H.I., Lee, V.M., Van Deerlin, V.M.
et al. (2013) Clinical and biochemical differences in patients
having Parkinson disease with vs without GBA mutations.
JAMA Neurol, 70, 852–858.
31. Schapira, A.H. (2015) Glucocerebrosidase and Parkinson dis-
ease: recent advances. Mol. Cell. Neurosci., 66, 37–42.
32. Murphy, K.E., Gysbers, A.M., Abbott, S.K., Tayebi, N., Kim, W.
S., Sidransky, E., Cooper, A., Garner, B. and Halliday, G.M.
(2014) Reduced glucocerebrosidase is associated with in-
creased alpha-synuclein in sporadic Parkinson’s disease.
Brain, 137, 834–848.
33. Cullen, V., Sardi, S.P., Ng, J., Xu, Y.H., Sun, Y., Tomlinson, J.J.,
Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J. et al. (2011) Acid
beta-glucosidase mutants linked to Gaucher disease, Parkin-
son disease, and Lewy body dementia alter alpha-synuclein
processing. Ann. Neurol., 69, 940–953.
34. Devi, L., Raghavendran, V., Prabhu, B.M., Avadhani, N.G. and
Anandatheerthavarada, H.K. (2008) Mitochondrial import
and accumulation of alpha-synuclein impair complex I in
human dopaminergic neuronal cultures and Parkinson dis-
ease brain. J. Biol. Chem., 283, 9089–9100.
35. Igisu, H., Hamasaki, N., Ito, A. and Ou, W. (1988) Inhibition of
cytochrome c oxidase and hemolysis caused by lysosphingo-
lipids. Lipids, 23, 345–348.
36. Brockmann, K., Hilker, R., Pilatus, U., Baudrexel, S., Srulijes,
K., Magerkurth, J., Hauser, A.K., Schulte, C., Csoti, I., Merten,
Human Molecular Genetics, 2015, Vol. 24, No. 23 | 6651
C.D. et al. (2012). Neurodegeneration, altered membrane me-
tabolism, and lack of energy failure. Neurology, 79, 213–220.
37. Frake, R.A., Ricketts, T., Menzies, F.M. and Rubinsztein, D.C.
(2015) Autophagy and neurodegeneration. J. Clin. Invest.,
125, 65–74.
38. Zancan, I., Bellesso, S., Costa, R., Salvalaio, M., Stroppiano, M.,
Hammond,C., Argenton, F., Filocamo,M. andMoro, E. (2015)Glu-
cocerebrosidase deﬁciency in zebraﬁsh affects primary bone os-
siﬁcation through increased oxidative stress and reduced Wnt/
beta-catenin signaling. Hum. Mol. Genet., 24, 1280–1294.
39. Ablain, J. and Zon, L.I. (2013) Of ﬁsh andmen: using zebraﬁsh
to ﬁght human diseases. Trends Cell. Biol., 23, 584–586.
40. Wyatt, C., Bartoszek, E.M. and Yaksi, E. (2015) Methods for
studying the zebraﬁsh brain: past, present and future.
Eur. J. Neurosci., 42, 1746–1763.
41. Dehay, B., Martinez-Vicente, M., Caldwell, G.A., Caldwell, K.
A., Yue, Z., Cookson, M.R., Klein, C., Vila, M. and Bezard, E.
(2013) Lysosomal impairment in Parkinson’s disease. Move-
ment Disord., 28, 725–732.
42. Murphy, K.E. andHalliday, G.M. (2014) Glucocerebrosidase def-
icits in sporadic Parkinson disease. Autophagy, 10, 1350–1351.
43. Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Vargh-
ese, S., Qureshi, M.M., Dardis, A., Deganuto, M., De Carlo, C.,
Castrioto, A. et al. (2014) Cerebrospinal ﬂuid lysosomal en-
zymes and alpha-synuclein in Parkinson’s disease.Movement
Disord., 29, 1019–1027.
44. Gegg,M.E., Burke, D., Heales, S.J., Cooper, J.M., Hardy, J.,Wood,
N.W. and Schapira, A.H. (2012) Glucocerebrosidase deﬁciency
in substantia nigra of parkinson disease brains. Ann. Neurol.,
72, 455–463.
45. Sardi, S.P., Clarke, J., Viel, C., Chan,M., Tamsett, T.J., Treleaven,
C.M., Bu, J., Sweet, L., Passini, M.A., Dodge, J.C. et al. (2013) Aug-
menting CNS glucocerebrosidase activity as a therapeutic
strategy for parkinsonism and other Gaucher-related synu-
cleinopathies. Proc. Natl Acad. Sci. U.S.A., 110, 3537–3542.
46. Flinn, L.,Mortiboys, H., Volkmann, K., Koster, R.W., Ingham, P.
W. and Bandmann, O. (2009) Complex I deﬁciency and dopa-
minergic neuronal cell loss in parkin-deﬁcient zebraﬁsh
(Danio rerio). Brain, 132, 1613–1623.
47. Bui, H.H., Leohr, J.K. and Kuo, M.S. (2012) Analysis of sphingo-
lipids in extracted human plasma using liquid chromatog-
raphy electrospray ionization tandem mass spectrometry.
Anal. Biochem., 423, 187–194.
48. Wilkinson, R.N., Elworthy, S., Ingham, P.W. and van Eeden, F.J.
(2013)Amethod for high-throughput PCR-based genotyping of
larval zebraﬁsh tail biopsies. BioTechniques, 55, 314–316.
49. Rink, E. andWullimann,M.F. (2001) The teleostean (zebraﬁsh)
dopaminergic system ascending to the subpallium (striatum)
is located in the basal diencephalon (posterior tuberculum).
Brain Res., 889, 316–330.
50. Rink, E. and Wullimann, M.F. (2002) Connections of the ven-
tral telencephalon and tyrosine hydroxylase distribution in
the zebraﬁsh brain (Danio rerio) lead to identiﬁcation of an
ascending dopaminergic system in a teleost. Brain Res. Bull.,
57, 385–387.
51. Sallinen, V., Torkko, V., Sundvik, M., Reenila, I., Khrustalyov,
D., Kaslin, J. and Panula, P. (2009) MPTP and MPP+ target spe-
ciﬁc aminergic cell populations in larval zebraﬁsh.
J. Neurochem., 108, 719–731.
52. Ellett, F., Pase, L., Hayman, J.W., Andrianopoulos, A. and
Lieschke, G.J. (2011)mpeg1 promoter transgenes directmacro-
phage-lineage expression in zebraﬁsh. Blood, 117, e49–e56.
53. Bai, Q., Parris, R.S. and Burton, E.A. (2014) Different mechan-
isms regulate expression of zebraﬁshmyelin protein zero (P0)
in myelinating oligodendrocytes and its induction following
axonal injury. J. Biol. Chem., 289, 24114–24128.
54. Bai, Q., Sun, M., Stolz, D.B. and Burton, E.A. (2011) Major iso-
form of zebraﬁsh P0 is a 23.5 kDa myelin glycoprotein ex-
pressed in selected white matter tracts of the central
nervous system. J. Comp. Neurol., 519, 1580–1596.
6652 | Human Molecular Genetics, 2015, Vol. 24, No. 23
